INDEMNIFICATION AGREEMENT Effective Date: , 2019Indemnification Agreement • December 31st, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”), is made as of the Effective Date set forth above, between NEUROBO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), whose address is 177 Huntington Avenue, Suite 1700, Boston, MA 02115, and (“Indemnitee”).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 31st, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Delaware
This CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of December 30, 2019 (the “Effective Date”), is entered into by and among Gemphire Therapeutics Inc., a Delaware corporation (“Parent”), Grand Rapids Holders’ Representative, LLC, as representative of the Holders (the “Holders’ Representative”), and Computershare Inc., as Rights Agent.
Consulting AgreementConsulting Agreement • December 31st, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (“Agreement”) is effective as of May 1, 2018 by and between NeuroBo Pharmaceuticals, Inc. (“NeuroBo”), a Massachusetts corporation with its principal place of business at 177 Huntington Avenue, Suite 1732, Boston, MA 02115 (email — jkang@jkbiopharma.com) and vZenium LLC (“Consultant”), a Massachusetts limited liability company, owned and managed entirely by Mark Versavel, MD, PhD, MBA with a principal place of business at 47 Marathon Street, Arlington, MA 02474 (email - mark.versavel@vzenium.com).
